Checking a blood test for tumor DNA in bladder and upper urinary tract cancer
Checks how well a blood test finds tumor DNA in people with bladder cancer.
Plain-language title generated from the registry record
Registry title: Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
Key facts
- Where
- Ghent, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with muscle-invasive bladder cancer or upper tract urothelial cancer, stage T2 or higher. Their tumor tissue and routine blood samples are tested for ctDNA.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Proven muscle-invasive bladder cancer, or suspected muscle-invasive upper tract urothelial cancer, stage T2 or higher.
- Biomarker or test result
- Tumor tissue must be available for DNA extraction (from bladder tumor removal, ureteroscopic biopsy, biopsy of a metastatic lesion, or kidney and ureter removal).
Main reasons for not taking part
- Another active cancer diagnosed within the past 5 years
Read by machine on 9 November 2026.
Where in Belgium
- AZ Sint-Lucas GentGhent, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AZ Sint-Lucas Gent
- Trial code
- NCT07756437
- Record updated
- 10 August 2026
- Original description
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer. ctDNA consists of small fragments of tumor DNA that can sometimes be detected in the blood.Read full original descriptionShow less
Internal Validation of Circulating Tumor DNA (ctDNA) Sequencing in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma: A Prospective Observational Study
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer. ctDNA consists of small fragments of tumor DNA that can sometimes be detected in the blood.
In this study, DNA from tumor tissue obtained during routine diagnostic or surgical procedures will be analyzed to identify tumor-specific mutations. Blood samples collected during routine clinical care will then be tested to determine whether the same mutations can be detected in plasma ctDNA.
The main purpose is to assess how well the internally developed ctDNA assay detects tumor-specific mutations compared with tumor tissue sequencing. The study will also explore whether ctDNA results after treatment are associated with recurrence or remission during two years of follow-up, and whether changes in ctDNA levels during treatment are associated with pathological response.
This study does not assign participants to a treatment and does not require additional blood draws beyond routine care. Treating physicians will remain blinded to ctDNA results during the study, so the test results will not influence clinical decisions.
Inclusion: Age 18 years or older; Histologically confirmed muscle-invasive bladder cancer or suspected muscle-invasive upper tract urothelial carcinoma, stage T2 or higher; Availability of tumor tissue from transurethral resection of bladder tumor, ureteroscopic biopsy, biopsy of a metastatic lesion, or nephroureterectomy for DNA extraction; Written informed consent provided.
Exclusion: Concurrent active malignancy diagnosed within the past 5 years.